HUTCHMED (China) Limited
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $548.5M | $630.2M | $838.0M | $426.4M | $356.1M | $228.0M | $204.9M | $214.1M |
| Cost of Revenue | $336.3M | $348.9M | $384.4M | $311.1M | — | — | — | — |
| Gross Profit | $212.2M | $281.3M | $453.6M | $115.3M | — | — | — | — |
| Gross Margin | 38.7% | 44.6% | 54.1% | 27.0% | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $148.3M | $212.1M | $302.0M | $386.9M | $299.1M | $174.8M | $138.2M | $114.2M |
| SG&A Expense | $66.7M | $64.3M | $79.8M | $92.2M | $89.3M | $50.0M | $39.2M | $30.9M |
| Operating Income | $-39.2M | $-43.7M | $18.4M | $-407.7M | $-328.3M | $-196.7M | $-146.4M | $-92.6M |
| Operating Margin | -7.1% | -6.9% | 2.2% | -95.6% | -92.2% | -86.3% | -71.4% | -43.3% |
| Interest Expense | — | — | $759.0K | $652.0K | $592.0K | $787.0K | $1.0M | $1.0M |
| Pretax Income | $498.7M | $-1.1M | $58.3M | $-410.4M | $-215.7M | $-189.7M | $-141.1M | $-86.7M |
| Income Tax Expense | $63.6M | $7.2M | $4.5M | $-283.0K | $11.9M | $4.8M | $3.3M | $4.0M |
| Net Income | $456.9M | $37.7M | $100.8M | $-360.8M | $-194.6M | $-125.7M | $-106.0M | $-74.8M |
| Net Margin | 83.3% | 6.0% | 12.0% | -84.6% | -54.7% | -55.2% | -51.7% | -34.9% |
| EPS (Basic) | $0.53 | $0.04 | $0.12 | $-0.43 | $-0.25 | $-0.18 | $-0.16 | $-0.01 |
| EPS (Diluted) | $0.52 | $0.04 | $0.12 | $-0.43 | $-0.25 | $-0.18 | $-0.16 | $-0.11 |
| Shares Outstanding (Basic) | 858.3M | 855.4M | 849.7M | 847.1M | 792.7M | 697.9M | 665.7M | 6.64B |
| Shares Outstanding (Diluted) | 872.9M | 872.8M | 869.2M | 847.1M | 792.7M | 697.9M | 665.7M | 664.3M |
| Dividends Per Share | — | — | — | — | — | — | — | — |